Provided by Tiger Fintech (Singapore) Pte. Ltd.

Arcturus Therapeutics Ltd.

12.89
+0.24001.90%
Post-market: 12.890.00000.00%19:34 EDT
Volume:340.93K
Turnover:4.32M
Market Cap:349.57M
PE:-4.30
High:12.94
Open:12.58
Low:12.11
Close:12.65
Loading ...

Company Profile

Company Name:
Arcturus Therapeutics Ltd.
Exchange:
NASDAQ
Establishment Date:
2013
Employees:
175
Office Location:
10628 Science Center Drive,Suite 250,San Diego,California,United States
Zip Code:
92121
Fax:
- -
Introduction:
Arcturus Therapeutics Holdings Inc., a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA. The company is developing ARCT-810 (LUNAR-OTC), a mRNA-based therapeutic candidate, which is in Phase 2 clinical trial for treating ornithine transcarbamylase deficiency; and ARCT-154 (LUNAR-COV19), a mRNA vaccine candidate that is in Phase 3 arm of a Phase 1/2/3 study in Vietnam for the treatment of COVID-19, as well as ARCT-032 (LUNAR-CF), a mRNA therapeutic candidate for cystic fibrosis. The company was founded in 2013 and is headquartered in San Diego, California.

Directors

Name
Position
Joseph E. Payne
President, Chief Executive Officer and Director
Peter Farrell
Chairman of the Board
Andy Sassine
Chief Financial Officer and Director
Edward W. Holmes
Director
James Barlow
Director
Jing L. Marantz
Director
John H. Markels
Director
Magda Marquet
Director

Shareholders

Name
Position
Joseph E. Payne
President, Chief Executive Officer and Director
Padmanabh Chivukula
Chief Scientific Officer and Chief Operating Officer
Andy Sassine
Chief Financial Officer and Director
Lance Kurata
Chief Legal Officer